![Mahadi Baig: U.S. FDA granted priority review of Johnson and Johnson Innovative Medicine’s subcutaneous treatment for patients with EGFR-mutated NSCLC](https://oncodaily.com/pub/uploads/2024/08/Mahadi-Baig_upscayl_2x_realesrgan-x4plus.png)
Photo taken from Mahadi Baig/LinkedIn
Aug 17, 2024, 08:15
Mahadi Baig: U.S. FDA granted priority review of Johnson and Johnson Innovative Medicine’s subcutaneous treatment for patients with EGFR-mutated NSCLC
Mahadi Baig,
Johnson and Johnson, shared a post on LinkedIn:“I’m pleased to announce that today, the U.S. FDA granted priority review of Johnson and Johnson Innovative Medicine’s application for a subcutaneous treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC).
This treatment, with its potential to transform the treatment experience for patients, clearly demonstrates our team’s unwavering commitment to a ‘patient-centric‘ approach to developing better therapies.
I am incredibly proud of this team as we continue to put patients at the forefront of everything we do.
Learn more about the submission.”
Source: Mahadi Baig/LinkedIn